. 2024 Mar 21;15:1340415. doi: 10.3389/fendo.2024.1340415

Table 2.

Serologic results in GO patients and healthy controls.

		Graves’ orbitopathy	Healthy controls	p-value
		Graves’ orbitopathy	Healthy controls	p-value	Current thyroid status	Euthyroidism	44 (39.6%)	20 (80%)	< 0.001^a
	Subclinical hypothyroidism	13 (11.7%)	4 (16%)
	Overt hypothyroidism	11 (9.9%)	1 (4%)
	Subclinical hyperthyroidism	28 (25.2%)	0 (0%)
	Overt hyperthyroidism	15 (13.5%)	0 (0%)
fT4	Median	20.7 (IQR 8.5)	18.4 (IQR 3.82)	< 0.05^b
(normal range 14 - 29 pmol/L)	Below normal limits	11 (9.9%)	1 (4%)	0.064^a
	Within normal limits	85 (76.6%)	24 (96%)
	Above normal limits	15 (13.5%)	0 (0%)
TSH	Median	1.12 (IQR 3.0)	1.84 (IQR 1.16)	< 0.05^b
(normal range 0.56 - 4.27 mIU/L)	Below normal limits	44 (39.6%)	0 (0%)	<0.001^a
	Within normal limits	46 (41.4%)	21 (84%)
	Above normal limits	21 (18.9%)	4 (16%)
TSI	Median	3.36 (IQR 8.29)	<0.10 (IQR 0.0)	< 0.001^b
(normal range < 0.55 IU/L)	Within normal limits	14 (12.6%)	25 (100%)	< 0.001^a
	Above normal limits	97 (87.4%)	0 (0%)	< 0.001^a
sIL-2R^c	Median	418 (IQR 225)	286 (IQR 149)	< 0.001^b
(normal range < 555 IU/mL)	Within normal limits	85 (76.6%)	25 (100%)	< 0.01^a
	Above normal limits	26 (23.4%)	0 (0%)	< 0.01^a

fT4 (free T4, thyroxine); sIL-2R (soluble interleukin-2 receptor); TSH (thyroid-stimulating hormone); TSI (thyroid-stimulating immunoglobulins).

a: Fisher’s exact test, Freeman-Halton extension when appropriate.

b: Mann-Whitney U test.